Abstract
Chemical modulation of a formerly disclosed DGAT-1 inhibitor resulted in the identification of a compound with a suitable profile for preclinical development. Optimisation of solubility is discussed and a PK/PD study is presented.
Keywords:
DGAT-1 inhibitors; Diacylglycerol acyltransferase type 1; Metabolic lability; Oxadiazole; Solubility; Thiadiazole.
Copyright © 2015 Elsevier Ltd. All rights reserved.
MeSH terms
-
Diacylglycerol O-Acyltransferase / antagonists & inhibitors*
-
Diacylglycerol O-Acyltransferase / metabolism
-
Dose-Response Relationship, Drug
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Oxadiazoles / chemical synthesis
-
Oxadiazoles / chemistry
-
Oxadiazoles / pharmacology*
-
Structure-Activity Relationship
-
Thiadiazoles / chemical synthesis
-
Thiadiazoles / chemistry
-
Thiadiazoles / pharmacology*
Substances
-
Enzyme Inhibitors
-
Oxadiazoles
-
Thiadiazoles
-
DGAT1 protein, human
-
Diacylglycerol O-Acyltransferase